Keywords: پمبرولوزومب; PD-L1; Pembrolizumab; Pneumonitis; Autopsy; Lung cancer;
مقالات ISI پمبرولوزومب (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: پمبرولوزومب; Chronic lymphocytic leukemia; Small lymphocytic lymphoma; CLL; Melanoma; Immune checkpoint inhibitors; Pembrolizumab; PD-1 inhibitor;
Keywords: پمبرولوزومب; Crystal-induced arthritis; Gout; CPPD; Pembrolizumab; Checkpoint inhibitor;
Keywords: پمبرولوزومب; Cervical cancer; Pembrolizumab; Immune checkpoint inhibition; Biomakers;
Keywords: پمبرولوزومب; Checkpoint inhibitors; Ipilimumab; Pembrolizumab; Nivolumab; Autoimmunity; Rheumatic manifestations; Psoriatic arthritis; Rheumatoid arthritis; Eosinophilic fasciitis; Sarcoidosis;
Keywords: پمبرولوزومب; Triple negative breast cancer; Avelumab; Pembrolizumab; Novolumab; Atezolizumab; Abemaciclib;
Keywords: پمبرولوزومب; Bayesian Markov model; Cost-effectiveness; First-line therapy; Immunotherapy; NSCLC; Pembrolizumab;
Keywords: پمبرولوزومب; Anti-PD1 receptor; BRAF 600E mutation; Melanoma; Pembrolizumab; Primary solitary cerebral malignant melanoma; Primary solitary intracranial malignant melanoma; CT; Computed tomography; GTR; Gross total removal; IQR; Interquartile range; MMM; Metastatic ma
Keywords: پمبرولوزومب; cardio-oncology; checkpoint inhibitor; ipilimumab; myocarditis; nivolumab; pembrolizumab; anti-CTLA4; anti-cytotoxic T-lymphocyte-associated protein 4; anti-PD1; anti-programmed cell death protein 1; anti-PDL1; anti-programmed death-ligand 1; AUC; area un
Keywords: پمبرولوزومب; Urothelial carcinoma; Immune-checkpoint inhibitors; Pembrolizumab; Atezolizumab; Avelumab; Durvalumab; Nivolumab; Ipilimumab; Combination therapy;
Keywords: پمبرولوزومب; Cervical cancer; Immune check-point; Immunotherapy; CTLA-4; PD-1; Ipilimumab; Pembrolizumab; Nivolumab;
Keywords: پمبرولوزومب; Chemotherapy; Oral cancer; Chemoradiation; Cisplatin; Cetuximab; Nivolumab; Pembrolizumab;
Keywords: پمبرولوزومب; 5-fluorouracil; imiquimod; ingenol mebutate; acitretin; American Joint Commission on Cancer; Brigham and Women's Hospital staging system; capecitabine; CDKN2A; cetuximab; chemotherapy; classification; cSCC; CT; cutaneous squamous cell carcinoma; familial
Keywords: پمبرولوزومب; Melanoma; Adjuvant treatment; Nivolumab; Pembrolizumab; Target therapy; New strategies;
Keywords: پمبرولوزومب; Brentuximab vedotin; checkpoint inhibitors; nivolumab; pembrolizumab; transplant;
Keywords: پمبرولوزومب; Melanoma; Checkpoint inhibitors; Ipilimumab; Nivolumab; Pembrolizumab; Immune-related adverse events;
Keywords: پمبرولوزومب; Immunotherapy; Pembrolizumab; Nivolumab; First-line; Non-small cell lung cancer;
Keywords: پمبرولوزومب; anti-programmed cell death-1 therapy; nivolumab; pembrolizumab; vitiligo; vitiligo-like lesions; Abs; antibodies; CXCL; C-X-C motif ligand; CXCR; C-X-C motif receptor; IFN; interferon; IL; interleukin; PD; programmed cell death; TNF; tumor necrosis fact
Keywords: پمبرولوزومب; advanced melanoma; cost-effectiveness; ipilimumab; pembrolizumab;
Keywords: پمبرولوزومب; cabozantinib; depigmentation; dyspigmentation; hyperpigmentation; hypopigmentation; imatinib; ipilimumab; nivolumab; pazopanib; pembrolizumab; pigmentary; repigmentation; sorafenib; sunitinib; vitiligo; AE; adverse event; Bcr-abl; breakpoint cluster regio
Keywords: پمبرولوزومب; Atezolizumab; ipilimumab; nivolumab; pembrolizumab; treatment-related death; tremelimumab;
Keywords: پمبرولوزومب; Immune checkpoint; Immunotherapy; Programmed death-1; Cytotoxic T lymphocyte associated protein â4; Pembrolizumab; Nivolumab;
Keywords: پمبرولوزومب; Immunotherapy; Pembrolizumab; Immune related adverse event; Encephalopathy; Non-small cell lung cancer;
Keywords: پمبرولوزومب; Atezolizumab; Chemotherapy; Docetaxel; Nivolumab; Pembrolizumab;
Keywords: پمبرولوزومب; lymphoma; pembrolizumab; programmed cell death-1; sarcoidosis; FDG; fludeoxyglucose; PD-1; programmed cell death-1;
Keywords: پمبرولوزومب; Checkpoint inhibitors; Ipilimumab; Pembrolizumab; Nivolumab; Organ transplantation; Rejection;
Keywords: پمبرولوزومب; Programmed cell death 1; PD-1; PDCD1; anti-PD-1 antibody; PD-1 inhibitor; nivolumab; pembrolizumab; acute interstitial nephritis (AIN); acute kidney injury (AKI); non-small cell lung cancer (NSCLC); advanced melanoma; ipilimumab; immune checkpoint inhib
Keywords: پمبرولوزومب; PD-1; PD-L1; Pembrolizumab; Immune checkpoints; Gastric cancer
Keywords: پمبرولوزومب; Monoclonal antibodies; Multiple myeloma; Bone disease; Daratumumab; Elotuzumab; Siltuximab; Lorvotuzumab; Pembrolizumab; Denosumab; BHQ880
Keywords: پمبرولوزومب; Immune-checkpoint inhibitors; Immune-related adverse events; Ipilimumab; Nivolumab; Pembrolizumab; Melanoma; Lung cancer; Renal cancer
Keywords: پمبرولوزومب; acute kidney injury; ipilimumab; nivolumab; pembrolizumab;
Keywords: پمبرولوزومب; Fatigue; ipilimumab; nivolumab; pembrolizumab; tremelimumab;
Keywords: پمبرولوزومب; PD-1; PD-L1; PD-L2; Lymphoid malignancies; Pidilizumab; Nivolumab; Pembrolizumab
Keywords: پمبرولوزومب; Microsatellite instability; Nivolumab; PD-L1; Pembrolizumab; TILs;
Keywords: پمبرولوزومب; Immune checkpoint inhibitors; Nivolumab; Atezolizumab; Pembrolizumab; Renal cell carcinoma; Urothelial carcinoma;
Successful treatment by pembrolizumab in a patient with end-stage renal disease with advanced non-small cell lung cancer and high PD-L1 expression
Keywords: پمبرولوزومب; Anti-PD-1-antibody; Chronic renal failure; End-stage renal disease; Hemodialysis; Pembrolizumab;
A successful pembrolizumab treatment case of lung adenocarcinoma after becoming resistant to ALK-TKI treatment due to G1202R mutation
Keywords: پمبرولوزومب; ALK-TKI; PD-1/PD-L1; Pembrolizumab; Precision medicine; G1202R;
Sarcoidosis post-anti-PD-1 therapy, mimicking relapse of metastatic melanoma in a patient undergoing complete remission
Keywords: پمبرولوزومب; Checkpoint inhibitors; Pembrolizumab; Immunotherapy; Anti-PD-1; Melanoma; Sarcoidosis;
Treatment of squamous cell carcinoma of the anal canal: A new strategies with anti-EGFR therapy and immunotherapy
Keywords: پمبرولوزومب; Anal cancer; Immunotherapy; Nivolumab; Anti-EGFR; Cetuximab; Pembrolizumab; Panitumumab;
First-line pembrolizumab in PD-L1 positive non-small-cell lung cancer: A cost-effectiveness analysis from the UK health care perspective
Keywords: پمبرولوزومب; Cost-Effectiveness; Immunotherapy; Non-small-cell lung cancer; Pembrolizumab;
Phase II Study of Maintenance Pembrolizumab in Patients with Extensive-Stage Small Cell Lung Cancer (SCLC)
Keywords: پمبرولوزومب; SCLC; Maintenance; Pembrolizumab; Metastatic;
How to Approach a Hodgkin Lymphoma Patient With Relapse After Autologous SCT: Allogeneic SCT
Keywords: پمبرولوزومب; Brentuximab vedotin; Checkpoint inhibitors; Haploidentical; Nivolumab; Pembrolizumab;
Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial
Keywords: پمبرولوزومب; Pembrolizumab; Melanoma; PD-1; PD-L1;
A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC
Keywords: پمبرولوزومب; NSCLC; programmed death 1 (PD-1); EGFR; tumor immunology; pembrolizumab; programmed death ligand 1;
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate rece
Keywords: پمبرولوزومب; Alefacept; Fingolimod; Infection; Ipilimumab; Natalizumab; Nivolumab; Pembrolizumab; Progressive multifocal leukoencephalopathy; Proteasome inhibitors; Vedolizumab;
Clinical outcomes with therapies for previously treated recurrent/metastatic head-and-neck squamous cell carcinoma (R/M HNSCC): A systematic literature review
Keywords: پمبرولوزومب; Head and neck squamous cell carcinoma; Systematic literature review; Platinum-based chemotherapy; Pembrolizumab; Nivolumab;
Safety and Efficacy of PD-1 Inhibitors Among HIV-Positive Patients With Non-Small Cell Lung Cancer
Keywords: پمبرولوزومب; Lung cancer; HIV; Pembrolizumab; Nivolumab; PD-1; PD-L1; Immunotherapy;
Establishment of engineered cell-based assays mediating LAG3 and PD1 immune suppression enables potency measurement of blocking antibodies and assessment of signal transduction
Keywords: پمبرولوزومب; LAG3; PD1; MK-4280; Pembrolizumab; Jurkat; Cell-based;
The changing scenario of 1st line therapy in non-oncogene addicted NSCLCs in the era of immunotherapy
Keywords: پمبرولوزومب; NSCLC; First line; Immunotherapy; Pembrolizumab; Nivolumab; Avelumab; Atezolizumab; Durvalumab;
The unique biology and treatment of primary mediastinal B-cell lymphoma
Keywords: پمبرولوزومب; Anti-PD-1; CD30; Brentuximab vedotin; CHOP; DA-EPOCH; MACOP-B; PD-1; JAK/STAT; Primary mediastinal large B-Cell lymphoma; Pembrolizumab; Radiotherapy; Rituximab; Ruxolitinib; VACOP-B;